Literature DB >> 2574645

Reasons for the variability in growth hormone (GH) responses to GHRH challenge: the endogenous hypothalamic-somatotroph rhythm (HSR).

J Devesa1, L Lima, N Lois, C Fraga, M J Lechuga, V Arce, J A Tresguerres.   

Abstract

The aims of this study were: (1) to test the possibility that pre-GHRH plasma GH values could reflect the functional status of the hypothalamic-somatotroph rhythm (HSR) at testing, and thus explain if it is responsible for the marked variability in GH responsiveness to GHRH challenge and (2) to see if exogenous somatostatin (SS) could disrupt this endogenous HSR and thus make the GH responses homogeneous. (1) Two to 14 GHRH acute tests (GRF-29, 1 micrograms/kg, i.v. bolus) were performed in 12 normal men and 10 normal women at the same time (0830 h) at random intervals (2 to 60 days). Blood samples to measure plasma GH were drawn at 15 min intervals before and after GHRH challenge. Given that the increments in pre-GHRH plasma GH values (I = value at 0 min minus value at -15 min) were highly correlated with either GHRH-elicited peaks of GH (men, r = 0.81; women; r = 0.69; P less than 0.0001) or the rise in GH after the challenge (r = 0.685; P less than 0.0001, in the total of tests performed), three theoretical HSR phases were proposed: (A) I greater than or equal to 0.4 microgram/l Secretory Phase; (B) I less than or equal to 0, (from GH at -15 min greater than or equal to 1.5 microgram/l), Secretion Plateau; (C) I less than or equal to 0, (from GH at -15 min less than or equal to 1.5 microgram/l), Refractory Phase. Individually, 91% of the men and 86% of the women showed a constant HSR phase when tested at the same time of day independently of the intervals between tests. GH responses (peaks, mean +/- SEM, g/l) in Phase A (women, 51.5 +/- 4.1; men, 31.4 +/- 3.2) were significantly higher (P less than 0.01) than those in Phase B (women, 22.6 +/- 1.8; men, 19.7 +/- 1.5), and these than those in Phase C (women, 9.2 +/- 1.5; men, 6.2 +/- 0.5). The great dispersion observed when GH peaks were analysed as a whole disappeared (except in Phase A in women) when they were evaluated according to the HSR Phase at testing. (2) In seven men and eight women 7 min after stopping an infusion of SS (250 micrograms/h for 3 h) a new GHRH test was performed. Plasma GH variations prior to SS infusion expressed the previous HSR Phase, while the GHRH-elicited peak of GH established the Phase at the moment of testing.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574645     DOI: 10.1111/j.1365-2265.1989.tb00434.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Growth hormone (GH) response to GH-releasing hormone in short children: lack of correlation with endogenous nocturnal GH secretion.

Authors:  S Seminara; A Filpo; P Piccinini; F La Cauza; M Cappa; A Faedda; S Loche
Journal:  J Endocrinol Invest       Date:  1997-03       Impact factor: 4.256

2.  One year treatment with clonidine in children with constitutional growth delay.

Authors:  B Moreno Esteban; S Monereo Mejías; P Rodríguez Poyo-Guerrero; F J Moreno Esteban; J A Tresguerres
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

Review 3.  Diagnosis of growth hormone deficiency in childhood.

Authors:  Takara Stanley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-02       Impact factor: 3.243

Review 4.  Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.

Authors:  Monica Gola; Mauro Doga; Stefania Bonadonna; Gherardo Mazziotti; Pier Paolo Vescovi; Andrea Giustina
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans.

Authors:  D Tepavcević; Z Giljević; I Aganović; M Korsić; S Halimi; E Suchanek; T Jelić; B Kozić; V Plavsić
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

6.  Effect of body mass index on peak growth hormone response to provocative testing in children with short stature.

Authors:  Takara L Stanley; Lynne L Levitsky; Steven K Grinspoon; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2009-11-04       Impact factor: 5.958

7.  Sex differences in growth hormone response to growth hormone-releasing hormone.

Authors:  P Benito; L Avila; M S Corpas; J A Jiménez; L Cacicedo; F Sánchez Franco
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

8.  Physiological levels of growth hormone fail to suppress growth hormone releasing hormone (1-29) NH2-stimulated growth hormone secretion in man.

Authors:  C Brain; D N Thakrar; P C Hindmarsh; C G Brook
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

9.  Secretion of growth hormone and thyroid-stimulating hormone in patients with dementia.

Authors:  J M Gómez; M Aguilar; M A Navarro; J Ortolá; J Soler
Journal:  Clin Investig       Date:  1994-07

10.  Influence of body mass index on the growth hormone response to provocative testing in short children without growth hormone deficiency.

Authors:  Jieun Lee; Juyoung Yoon; Min Jae Kang; Young Ah Lee; Seong Yong Lee; Choong Ho Shin; Sei Won Yang
Journal:  J Korean Med Sci       Date:  2013-08-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.